Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herceptin SC + Perjeta + docetaxel safety study in HER2-positive advanced breast cancer
2014-001458-40Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of trastuzumab, pertuzumab and docetaxel in breast cancer, sponsored by Roche. Primary endpoint: Incidence and severity of adverse events grade 3 or higher. Started Dec 2014; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2014-001458-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001458-40.